169 related articles for article (PubMed ID: 1534640)
1. Comparative immunogenicity in children of mammalian cell-derived recombinant hepatitis B vaccine and plasma-derived hepatitis B vaccine.
Coursaget P; Bringer L; Sarr G; Bourdil C; Fritzell B; Blondeau C; Yvonnet B; Chiron JP; Jeannée E; Guindo S
Vaccine; 1992; 10(6):379-82. PubMed ID: 1534640
[TBL] [Abstract][Full Text] [Related]
2. [Immunogenicity and harmlessness in the newborn of a vaccine (GenHevac B) containing the antigens S and pre-S2].
Tron F; Soulié JC; Goudeau A; Devillier P; Saliou P
Bull Soc Pathol Exot; 1991; 84(5 Pt 5):901-5. PubMed ID: 1840243
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety in newborns of a new recombinant hepatitis B vaccine containing the S and pre-S2 antigens.
Soulié JC; Devillier P; Santarelli J; Goudeau A; Vermeulen P; Guellier M; Saliou P; Hillion AM; Tron F; Huchet J
Vaccine; 1991 Aug; 9(8):545-8. PubMed ID: 1837646
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of a recombinant Pre-S2-containing hepatitis B vaccine versus plasma-derived vaccine administered as a booster.
Bucher B; Francioli P; Geudelin B; Fritzell B; Lavanchy D; Frei PC
Eur J Clin Microbiol Infect Dis; 1994 Mar; 13(3):212-7. PubMed ID: 8050433
[TBL] [Abstract][Full Text] [Related]
5. Comparative safety and immunogenicity of yeast recombinant hepatitis B vaccines containing S and pre-S2 + S antigens.
Miskovsky E; Gershman K; Clements ML; Cupps T; Calandra G; Hesley T; Ioli V; Ellis R; Kniskern P; Miller W
Vaccine; 1991 May; 9(5):346-50. PubMed ID: 1872019
[TBL] [Abstract][Full Text] [Related]
6. [Recombinant vaccine and extracting vaccine against hepatitis B in patients with kidney insufficiency: comparative immunogenicity].
Jungers P; Chauveau P; Couroucé AM; Abbassi A; Devillier P; Marie FN; Bailleux F; Excler JL; Cerisier JE; Saliou P
Presse Med; 1994 Feb; 23(6):277-80. PubMed ID: 8208677
[TBL] [Abstract][Full Text] [Related]
7. Comparison of results of recombinant and plasma-derived hepatitis B vaccines in Japanese nursery-school children.
Hayashi J; Kashiwagi S; Kajiyama W; Ikematsu H; Noguchi A; Nomura H; Ikeda K
J Infect; 1988 Jul; 17(1):49-55. PubMed ID: 2974467
[TBL] [Abstract][Full Text] [Related]
8. The safety and immunogenicity of a recombinant hepatitis B vaccine in neonates.
Gunn TR; Bosley A; Woodfield DG
N Z Med J; 1989 Jan; 102(860):1-3. PubMed ID: 2521527
[TBL] [Abstract][Full Text] [Related]
9. Antibody responses to recombinant, yeast-derived hepatitis B vaccine in teenage New Zealand children.
Milne A; Moyes CD; Allwood GK; Pearce NE; Krugman S
N Z Med J; 1988 Feb; 101(840):67-9. PubMed ID: 2967940
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of the recombinant GenHevac B Pasteur vaccine against hepatitis B in chronic uremic patients.
Jungers P; Chauveau P; Couroucé AM; Devillier P; Excler JL; Bailleux F; Saliou P
J Infect Dis; 1994 Feb; 169(2):399-402. PubMed ID: 8106774
[TBL] [Abstract][Full Text] [Related]
11. Immune response to simultaneous administration of a recombinant DNA hepatitis B vaccine and multiple compulsory vaccines in infancy.
Giammanco G; Li Volti S; Mauro L; Bilancia GG; Salemi I; Barone P; Musumeci S
Vaccine; 1991 Oct; 9(10):747-50. PubMed ID: 1836919
[TBL] [Abstract][Full Text] [Related]
12. Reactogenicity and immunogenicity of a new recombinant yeast-derived hepatitis B vaccine.
Scheiermann N; Gesemann KM; Paar D; Maurer C
Zentralbl Bakteriol Mikrobiol Hyg A; 1988 Nov; 269(3):411-21. PubMed ID: 2975448
[TBL] [Abstract][Full Text] [Related]
13. Anti-HBs levels in infants of hepatitis B carrier mothers after delayed active immunization with recombinant vaccine concomitant with DTP-polio vaccine: is there need for a second dose of HBIg? Dutch Study Group on Prevention of Neonatal Hepatitis B.
Grosheide PM; del Canho R; Voogd M; Heijtink RA; Schalm SW
Vaccine; 1994 Sep; 12(12):1059-63. PubMed ID: 7998413
[TBL] [Abstract][Full Text] [Related]
14. Comparison of immunogenicity of two yeast-derived recombinant hepatitis B vaccines.
Hammond GW; Parker J; Mimms L; Tate R; Sekla L; Minuk G
Vaccine; 1991 Feb; 9(2):97-100. PubMed ID: 1829306
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a recombinant hepatitis B vaccine in patients infected with Schistosoma mansoni.
Bassily S; Hyams KC; el-Ghorab N; el-Masry NA
Am J Trop Med Hyg; 1990 May; 42(5):449-52. PubMed ID: 2140243
[TBL] [Abstract][Full Text] [Related]
16. Randomized dose range study of a recombinant hepatitis B vaccine produced in mammalian cells and containing the S and PreS2 sequences.
Tron F; Degos F; Bréchot C; Couroucé AM; Goudeau A; Marie FN; Adamowicz P; Saliou P; Laplanche A; Benhamou JP
J Infect Dis; 1989 Aug; 160(2):199-204. PubMed ID: 2527274
[TBL] [Abstract][Full Text] [Related]
17. Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis B vaccine following two different schedules.
Scheiermann N; Gesemann M; Maurer C; Just M; Berger R
Vaccine; 1990 Mar; 8 Suppl():S44-6; discussion S60-2. PubMed ID: 2139282
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of low dose intradermally administered hepatitis B vaccine: a comparison of plasma-derived and recombinant yeast-derived vaccines.
Söyletir G; Bahçeci E; Akoğlu E; Soyoğul U; Lawrance RA
Vaccine; 1992; 10(5):301-4. PubMed ID: 1533478
[TBL] [Abstract][Full Text] [Related]
19. Persistence of antibodies following vaccination with a yeast-derived recombinant hepatitis B vaccine.
Just M; Berger R; Scheiermann N
Vaccine; 1988 Oct; 6(5):401-2. PubMed ID: 2973694
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of recombinant hepatitis B vaccine in infants born to HBsAg-positive mothers.
Yeoh EK; Chang WK; Ip P; Chan KH; Chan E; Fung C
J Infect; 1986 Jul; 13 Suppl A():15-8. PubMed ID: 2943811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
